{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"title":"Baseline Transfusion Dependent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Baseline Transfusion Independent"}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"}],"units":"Participants"}],"description":"Participants who achieved 56-day post-baseline red blood cell (RBC) transfusion independence, i.e. with no RBC transfusions for at least 56 consecutive days during the treatment exposure period, reported by Baseline RBC transfusion dependence status. Participants with at least one transfusion during the Baseline period were considered transfusion dependent at Baseline, where the Baseline period is defined as 56 days before the first dose date for Phase 2.","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"NUMBER","populationDescription":"All participants In Phase 2 with R/R AML who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).","title":"Phase 2: Percentage of Participants Who Achieved 56-Day Red Blood Cell Transfusion Independence Post-baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}